CRL · Charles River Laboratories International, Inc.
$173.892026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
Base · active
$64
-62.9% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($68 · $-340) Analysts Range ($175 · $260) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $3.5B | — | 16.7% | 17.0% | $489MM | −$1.1B | −$601MM | 11.0% | — | 9.3% | $5.2B | $7.94 | — |
| 2022.Q4 | $4.0B | 12.3% | 16.4% | 20.9% | $515MM | −$294MM | $221MM | 11.0% | — | 9.6% | $5.5B | $9.88 | — |
| 2023.Q4 | $4.1B | 3.9% | 14.9% | 17.4% | $510MM | −$310MM | $200MM | 10.8% | — | 8.9% | $6.0B | $9.64 | — |
| 2024.Q4 | $4.0B | -1.9% | 5.6% | 45.0% | $125MM | $93MM | $218MM | 10.9% | — | 2.2% | $5.5B | $0.21 | — |
| 2025.Q4 | $4.0B | -0.9% | 10.7% | 0.0% | $613MM | $217MM | $830MM | 13.4% | — | 11.1% | $5.6B | $-2.93 | 20.0 |
| italics below = DCF projection · 10yr Rev CAGR: 4.1% |
| 2026.Q4 | $4.0B | +-0.5% | 12.7% | 2.0% | $497MM | $0MM | $497MM | 11.4% | $446MM | 8.9% | $5.6B | $10.09 | 17.2 |
| 2027.Q4 | $4.1B | +3.5% | 12.7% | 4.0% | $503MM | −$10MM | $493MM | 11.2% | $398MM | 9.1% | $5.6B | $10.23 | 17.0 |
| 2028.Q4 | $4.3B | +4.5% | 12.7% | 6.0% | $515MM | −$25MM | $489MM | 10.9% | $356MM | 9.2% | $5.6B | $10.46 | 16.6 |
| 2029.Q4 | $4.6B | +5.5% | 12.7% | 8.0% | $532MM | −$853MM | −$322MM | 10.6% | −$212MM | 8.8% | $6.4B | $10.80 | 16.1 |
| 2030.Q4 | $4.8B | +5.3% | 12.7% | 10.0% | $547MM | −$754MM | −$206MM | 10.3% | −$123MM | 8.0% | $7.2B | $11.12 | 15.6 |
|
| Term. Yr+ | $6.2B | 4.1% | 19.6% | 20.0% | $976MM | −$466MM | $511MM | 8.6% | $4.3B | 8.6% | — | — | — |
Active scenario IV: $64 (-62.9% vs market)